Search Results

• • 22 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• How to screen - and what the results mean

  Author:Donald L. TrumpFrom:Consultant (Vol. 32, Issue 8) Peer-Reviewed

  Aug. 19923,596 words Article ABSTRACT: Age, race, and family history remain the three most important factors in assessing a patient's risk of prostate cancer. Recent research suggests diet also plays a role; a low-fiber, high-fat diet may be...

• Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor

  Authors:Joan H. Schiller, Patricia L. Witt, Barry Storer, Dona Alberti, Mary Beth Tombes, Rhoda Arzoomanian, et al.From:Cancer (Vol. 69, Issue 2) Peer-Reviewed

  Jan. 15, 1992 Article

   Citation Only

• Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series Study

  Authors:Song Yao, Lara E. Sucheston, Amy E. Millen, Candace S. Johnson, Donald L. Trump, Mary K. Nesline, et al.From:PLoS ONE (Vol. 6, Issue 2) Peer-Reviewed

  Feb. 28, 20115,253 words Case study, Report 1640LBackground Results from epidemiologic studies on the relationship between vitamin D and breast cancer risk are inconclusive. It is possible that vitamin D may be effective in reducing risk only of specific subtypes...

• 1,25D3 Enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models

  Authors:Yingyu Ma, Wei-Dong Yu, Donald L. Trump, and Candace S. JohnsonFrom:Cancer (Vol. 116, Issue 13) Peer-Reviewed

  July 1, 2010 Clinical report

   Citation Only

• Early Growth Inhibition Is Followed by Increased Metastatic Disease with Vitamin D (Calcitriol) Treatment in the TRAMP Model of Prostate Cancer

  Authors:Adebusola Alagbala Ajibade, Jason S. Kirk, Ellen Karasik, Bryan Gillard, Michael T. Moser, Candace S. Johnson, et al.From:PLoS ONE (Vol. 9, Issue 2) Peer-Reviewed

  Feb. 26, 20147,902 words Article 1530LAuthor(s): Adebusola Alagbala Ajibade 1, Jason S. Kirk 1, Ellen Karasik 1, Bryan Gillard 1, Michael T. Moser 1, Candace S. Johnson 1, Donald L. Trump 2, Barbara A. Foster 1,* Introduction Prostate cancer (PCa) is...

• High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine

  Authors:Donald L. Trump, David C. Smith, Peter G. Ellis, Miriam P. Rogers, S. Clifford Schold, Eric P. Winer, et al.From:Journal of the National Cancer Institute (Vol. 84, Issue 23) Peer-Reviewed

  Dec. 2, 1992382 words Article

   Abstract Only

• Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

  Authors:Guru Sonpavde, Bryan H. Goldman, V.O. Speights, Seth P. Lerner, David P. Wood, Nicholas J. Vogelzang, et al.From:Cancer (Vol. 115, Issue 18) Peer-Reviewed

  Sept. 15, 2009 Clinical report

   Citation Only

• "Eight-drugs-in-one-day" chemotherapy administered before and after radiotherapy to adult patients with malignant gliomas

  Authors:Jack M. Rozental, H. Ian Robins, Jonathan Finlay, Barbara Healey, Allan B. Levin, Richard A. Steeves, et al.From:Cancer (Vol. 63, Issue 12) Peer-Reviewed

  June 15, 1989234 words Article

   Abstract Only

• Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882); An eastern cooperative oncology group study

  Authors:Andrea N. Leaf, Kathleen Propert, Chris Corcoran, Paul J. Catalano, Donald L. Trump, Jules E. Harris, et al.From:Medical Oncology (Vol. 20, Issue 2) Peer-Reviewed

  June 2003437 words Article

   Abstract Only

• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

  Authors:H. Barton Grossman, Ronald B. Natale, Catherine M. Tangen, V.O. Speights, Nicholas J. Vogelzang, Donald L. Trump, et al.From:The New England Journal of Medicine (Vol. 349, Issue 9) Peer-Reviewed

  Aug. 28, 200352 words Article

   Citation Only

• Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial

  Authors:Susan L. Greenspan, Joel B. Nelson, Donald L. Trump, and Neil M. ResnickFrom:Annals of Internal Medicine (Vol. 146, Issue 6) Peer-Reviewed

  Mar. 20, 2007301 words Author abstract

   Abstract Only

• Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP

  Authors:Susan E. Steck, Lenore Arab, Hongmei Zhang, Jeannette T. Bensen, Elizabeth T. H. Fontham, Candace S. Johnson, et al.From:PLoS ONE (Vol. 10, Issue 4) Peer-Reviewed

  Apr. 28, 20156,789 words Article 1640LBackground African Americans (AAs) have lower circulating 25-hydroxyvitamin D3 [25(OH)D3] concentrations and higher prostate cancer (CaP) aggressiveness than other racial/ethnic groups. The purpose of the current...

• An Eastern Cooperative Oncology Group Phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma

  Authors:Robert S. Witte, Paul Elson, Janardan Khandakar, and Donald L. TrumpFrom:Cancer (Vol. 73, Issue 3) Peer-Reviewed

  Feb. 1, 1994158 words Article

   Abstract Only

• Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (Calcitriol) in combination with dexamethasone for castration-resistant prostate cancer

  Authors:Manpreet K. Chadha, Lili Tian, Terry Mashtare, Valencia Payne, Carrie Silliman, Ellis Levine, et al.From:Cancer (Vol. 116, Issue 9) Peer-Reviewed

  May 1, 2010 Clinical report

   Citation Only

• Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone

  Authors:Wei-Dong Yu, Mariann C. McElwain, Ruth A. Modzelewski, Derick M. Russell, David C. Smith, Donald L. Trump, et al.From:Journal of the National Cancer Institute (Vol. 90, Issue 2) Peer-Reviewed

  Jan. 21, 1998260 words Article

   Abstract Only

• PSA screening on trial

  Authors:Leonard Sadoff and Donald L. TrumpFrom:Consultant (Vol. 39, Issue 10) Peer-Reviewed

  Oct. 1999953 words Article Prostate specific antigen (PSA) screening enables the early detection of prostate cancer. However, many oncologists remain skeptical since PSA has not been proven to save lives or improve survival of men at risk. Many...

• Psychological and mood disturbance associated with the diagnosis and treatment of testis cancer and other malignancies

  Authors:James F. Malec, Ellen P. Romsaas, Edward M. Messing, Kenneth C. Cummings, and Donald L. TrumpFrom:Journal of Clinical Psychology (Vol. 46, Issue 5) Peer-Reviewed

  Sept. 1990116 words Article

   Abstract Only

• Stat3 activation of NF-[kappa]B p100 processing involves CBP/p300-mediated acetylation

  Authors:Nagalakshmi Nadiminty, Wei Lou, Soo Ok Lee, Xin Lin, Donald L. Trump, and Allen C. GaoFrom:Proceedings of the National Academy of Sciences of the United States (Vol. 103, Issue 19) Peer-Reviewed

  May 9, 2006157 words Author abstract 60L

   Abstract Only

• Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer

  Authors:Donald L. Trump, Douglas M. Potter, Josephia Muindi, Adam Brufsky, and Candace S. JohnsonFrom:Cancer (Vol. 106, Issue 10) Peer-Reviewed

  May 15, 2006 Article

   Citation Only

• Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer

  Authors:Linda J. Hoffman, Clareann H. Bunker, Philip E. Pellett, Donald L. Trump, Alan L. Patrick, Sheila C. Dollard, et al.From:Journal of Infectious Diseases (Vol. 189, Issue 1) Peer-Reviewed

  Jan. 1, 2004 Article

   Citation Only